## PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY	•
To: ROBERT L. BUCHANAN EDWARDS & ANGELL, LLP P.O. BOX 55874	PCT  WRITTEN OPINION OF THE
BOSTON, MA 02205	INTERNATIONAL SEARCHING AUTHORITY
	(PCT Rule 43bis.1)
	Date of mailing (day/month/year) 31 MAR 2005
Applicant's or agent's file reference 62446-PCT	FOR FURTHER ACTION See paragraph 2 below
International application No. International filing date	e (day/month/year) Priority date (day/month/year)
PCT/US04/40403 03 December 2004 (03	.12.2004) 03 December 2003 (03.12.2003)
International Patent Classification (IPC) or both national classific	ation and IPC
IPC(7): A61K 31/55 and US Cl.: 514/221 Applicant	
VELA PHARMACEUTICALS, INC.	
1. This opinion contains indications relating to the following ite	ms:
Box No. I Basis of the opinion	
Box No. II Priority	
Box No. III Non-establishment of opinion with r	egard to novelty, inventive step and industrial applicability
Box No. IV Lack of unity of invention	
Box No. V Reasoned statement under Rule 43bi applicability; citations and explanation	s.1(a)(i) with regard to novelty, inventive step or industrial ons supporting such statement
Box No. VI Certain documents cited	:
Box No. VII Certain defects in the international a	pplication
Box No. VIII Certain observations on the internation	onal application
2. FURTHER ACTION	
International Preliminary Examining Authority ("IPEA") e	de, this opinion will be considered to be a written opinion of the xcept that this does not apply where the applicant chooses an IPEA has notified the International Bureau under Rule 66.1bis(b) will not be so considered.
If this opinion is, as provided above, considered to be a writ IPEA a written reply together, where appropriate, with an mailing of Form PCT/ISA/220 or before the expiration of 22 For further options, see Form PCT/ISA/220.	ten opinion of the IPEA, the applicant is invited to submit to the nendments, before the expiration of 3 months from the date of months from the priority date, whichever expires later.
3. For further details, see notes to Form PCT/ISA/220.	·
	LAutoria J 655 /c
Name and mailing address of the ISA/ US  Mail Stop PCT, Attn: ISA/US  Commissioner for Patents	Authorized officer  Kevin E. Weddington Clein Jel Charles  Option
P.O. Box 1450 Alexandria, Virginia 22313-1450	Telephone No. (703) 308-1234

Facsimile No. (703) 305-3230
Form PCT/ISA/237 (cover sheet) (January 2004)

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/40403

Box No. I Basis of this opinion	_
	٠
1. With regard to the language, this opinion has been established on the basis of the international application in the language in whit it was filed, unless otherwise indicated under this item.	ch
This opinion has been established on the basis of a translation from the original language into the following language which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).	_,
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:	
a. type of material	
a sequence listing	
table(s) related to the sequence listing	
b. format of material	
in written format	
in computer readable form	
c. time of filing/furnishing	
contained in international application as filed.	
filed together with the international application in computer readable form.	
furnished subsequently to this Authority for the purposes of search.	
In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	İ
4. Additional comments:	
·	
	4

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US04/40403

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement 1. Statement YES Claims 1-21 Novelty (N) NO Claims NONE YES Inventive step (IS) Claims 1-21 NO Claims NONE YES Claims 1-21 Industrial applicability (IA) NO Claims NONE 2. Citations and explanations: Claims 1-21 meet the criteria set out in PCT Article 33(2) as having novelty in the pharmaceutical art. Claims 1-21 meet the criteria set out in PCT Article 33(3) as having an inventive step in the pharmaceutical art. Claims 1-21 meet the criteria set out in PCT Article 33(4) as having industrial applicability in the pharmaceutical art.

Form PCT/ISA/237 (Box No. V) (January 2004)